NCT07225439 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT07225439
Title	Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Recruitment	Not yet recruiting
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	Paolo Caimi, MD
Indications	marginal zone lymphoma high-grade B-cell lymphoma double-hit/triple-hit mantle cell lymphoma diffuse large B-cell lymphoma follicular lymphoma primary mediastinal B-cell lymphoma chronic lymphocytic leukemia/small lymphocytic lymphoma
Therapies	Aldesleukin + Rituximab + Tafasitamab-cxix Cyclophosphamide + Fludarabine
Age Groups:	adult \| senior
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center		Cleveland	Ohio	44106	United States	Details
Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute		Cleveland	Ohio	44195	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT07225439Clinical Trial Detail